Table 4.
Clinical Characteristics of Studied AML Cases According to CXCR4 Positivity and SDF-1 Genotypes
| Clinical data | CXCR4 expression | P | SDF-1 genotypes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Negative (n=36) | Positive (n=24) | GG (n=32) | (A) allele carrier (n=28) | p | ||||||
| No | % | No | % | No | % | No | % | |||
| Age | ||||||||||
| Age <60 | 29 | 80.6 | 23 | 95.8 | 0.128 | 26 | 81.3 | 26 | 92.9 | 0.264 |
| Age ≥60 | 7 | 19.4 | 1 | 4.2 | 6 | 18.8 | 2 | 7.1 | ||
| TLCx109/l | ||||||||||
| Median | 54 | 64 | 0.251 | 57 | 59 | 0.87 | ||||
| Min - Max | 1-236 | 1-214 | 3-207 | 1-236 | ||||||
| BM blast cells | ||||||||||
| Median | 92 | 93.5 | 0.221 | 90 | 92 | 0.3 | ||||
| Min - Max | 23-100 | 28-100 | 23-100 | 33-99 | ||||||
| FAB classification | ||||||||||
| M1/M2 | 12 | 33.3 | 6 | 25 | 0.145 | 10 | 31.3 | 8 | 28.6 | 0.97 |
| M4-5 | 20 | 55.6 | 18 | 75 | 20 | 62.5 | 18 | 64.3 | ||
| M7 | 4 | 11.1 | 0 | 0 | 2 | 6.3 | 2 | 7.1 | ||
| Clinical presentation | ||||||||||
| Toxic manifestations (n=34) | 16 | 44.4 | 18 | 75 | 0.019 | 15 | 46.9 | 19 | 67.9 | 0.102 |
| Extramedullary infiltration (EMI) (n=51) | 28 | 77.8 | 23 | 95.8 | 0.072 | 27 | 84.4 | 24 | 85.7 | 0.885 |
| Cytogenetics risk stratification | ||||||||||
| Favorable | 17 | 47.2 | 4 | 16.7 | 12 | 37.5 | 9 | 32.1 | 0.488 | |
| Intermediate | 9 | 25 | 6 | 25 | 6 | 18.8 | 9 | 32.1 | ||
| Unfavorable | 10 | 27.8 | 14 | 58.3 | 0.027 | 14 | 43.8 | 10 | 35.8 | |
| Response rate | ||||||||||
| CR | 16 | 44.4 | 2 | 8.3 | 0.004 | 8 | 25 | 10 | 35.7 | 0.366 |
| Non-CR (RD-ID) | 20 | 55.6 | 22 | 91.7 | 24 | 75 | 18 | 64.3 | ||
CR, Complete response; ID, Induction death; RD, Refractory disease; TLC, Total leucocytic count.